ExploreIterate

Arthur DeCillis

Chief Medical Officer

Prior to forming his own consulting practice, Arthur “Art” DeCillis, MD was the Chief Medical Officer for Eleven Biotherapeutics (now known as Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previously, Art was the Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, Inc., an oncology-focused biotechnology company. He also previously served as Executive Director of Oncology Development at Novartis and Group Director of Bristol-Myers Squibb. Art has been involved in the development of several commercialized oncology drugs including SPRYCEL® (dasatinib), AFINITOR® (everolimus), FARYDAK® (panobinostat), and CABOMETYX® (cabozantinib).


Art holds an M.D. from University of Rochester and completed an internal medicine residency at Medical College of Virginia followed by a fellowship at University of Pittsburgh.


Social

Roles at Monopteros

  • Chief Medical Officer

    Current role


My work style

How I prefer to work

Qualities I value in my colleagues

Sign up to see more about the team at Monopteros

My pet peeves

My communication style

Org chart

Direct reports

No reports

Teams

No teams